<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36341232</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trial.</ArticleTitle><Pagination><StartPage>994911</StartPage><MedlinePgn>994911</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">994911</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.994911</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Research in recent years has shown the potential benefits of fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS). Acute infectious gastroenteritis is a well-established risk factor for developing such forms of IBS as post-infectious IBS (PI-IBS). However, the effective use of FMT in patients with IP-IBS has not yet been clarified.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">The study aimed to conduct a single-center, randomized clinical trial (RCT) to assess FMT's safety, clinical and microbiological efficacy in patients with PI-IBS.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Patients with PI-IBS were randomized into two groups: I (standard-care, <i>n</i> = 29) were prescribed basic therapy, namely a low FODMAP diet, as well as Otilonium Bromide (1 tablet TID) and a multi-strain probiotic (1 capsule BID) for 1 month; II (FMT group, <i>n</i> = 30), each patient with PI-IBS underwent a single FMT procedure with fresh material by colonoscopy. All patients underwent bacteriological examination of feces for quantitative and qualitative microbiota composition changes. The clinical efficacy of treatment was evaluated according to the dynamics of abdominal symptoms, measured using the IBS-SSS scale, fatigue reduction (FAS scale), and a change in the quality of life (IBS-QoL scale).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">FMT was associated with rapid onset of the effect, manifested in a significant difference between IBS-SSS points after 2 weeks of intervention (<i>p</i> &lt; 0.001). In other time points (after 4 and 12 weeks) IBS-SSS did not differ significantly across both groups. Only after 3 months of treatment did their QoL exceed its initial level, as well value for 2 and 4 weeks, to a significant extent. The change in the ratio of the main microbial phenotypes in the form of an increase in the relative abundance of <i>Firmicutes</i> and <i>Bacteroidetes</i> was recorded in all patients after 4 weeks. It should be noted that these changes were significant but eventually normalized only in the group of PI-IBS patients who underwent FMT. No serious adverse reactions were noted.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This comparative study of the results of FMT use in patients with PI-IBS demonstrated its effectiveness compared to traditional pharmacotherapy, as well as a high degree of safety and good tolerability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Tkach, Dorofeyev, Kuzenko, Sulaieva, Falalyeyeva and Kobyliak.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tkach</LastName><ForeName>Sergii</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorofeyev</LastName><ForeName>Andrii</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzenko</LastName><ForeName>Iurii</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulaieva</LastName><ForeName>Oksana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Medical Laboratory CSD, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falalyeyeva</LastName><ForeName>Tetyana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical Laboratory CSD, Kyiv, Ukraine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Educational-Scientific Center, "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobyliak</LastName><ForeName>Nazarii</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Laboratory CSD, Kyiv, Ukraine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Endocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diarrhea</Keyword><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">fecal microbiota transplantation</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">post-infectious irritable bowel syndrome</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>7</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36341232</ArticleId><ArticleId IdType="pmc">PMC9631772</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.994911</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet (London, England). (2020) 396:1675&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. (2015) 313:949&#x2013;58. 10.1001/JAMA.2015.0954</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2015.0954</ArticleId><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. (2014) 20:6759&#x2013;73. 10.3748/WJG.V20.I22.6759</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/WJG.V20.I22.6759</ArticleId><ArticleId IdType="pmc">PMC4051916</ArticleId><ArticleId IdType="pubmed">24944467</ArticleId></ArticleIdList></Reference><Reference><Citation>Codling C, O&#x2019;Mahony L, Shanahan F, Quigley EMM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. (2010) 55:392&#x2013;7. 10.1007/s10620-009-0934-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0934-x</ArticleId><ArticleId IdType="pubmed">19693670</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): interaction with gut microbiota and gut hormones. Nutrients. (2019) 11:1824. 10.3390/NU11081824</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/NU11081824</ArticleId><ArticleId IdType="pmc">PMC6723613</ArticleId><ArticleId IdType="pubmed">31394793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Gwee KA. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link. Nat Rev Gastroenterol Hepatol. (2017) 14:435&#x2013;41. 10.1038/NRGASTRO.2017.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NRGASTRO.2017.37</ArticleId><ArticleId IdType="pubmed">28513629</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. (2009) 136:1979&#x2013;88. 10.1053/J.GASTRO.2009.02.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/J.GASTRO.2009.02.074</ArticleId><ArticleId IdType="pubmed">19457422</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology. (2017) 152:1042&#x2013;54. 10.1053/J.GASTRO.2016.12.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/J.GASTRO.2016.12.039</ArticleId><ArticleId IdType="pmc">PMC5367939</ArticleId><ArticleId IdType="pubmed">28069350</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. (2018) 67:1078&#x2013;86. 10.1136/GUTJNL-2017-313713</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/GUTJNL-2017-313713</ArticleId><ArticleId IdType="pubmed">28601847</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G, Grover M, Bercik P, Corsetti M, Ghoshal UC, Ohman L, et al. Rome foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. (2019) 156:46&#x2013;58. 10.1053/J.GASTRO.2018.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/J.GASTRO.2018.07.011</ArticleId><ArticleId IdType="pmc">PMC6309514</ArticleId><ArticleId IdType="pubmed">30009817</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Hasler WL. Rome IV-Functional GI disorders: disorders of gut-brain interaction. Gastroenterology. (2016) 150:1257&#x2013;61. 10.1053/J.GASTRO.2016.03.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/J.GASTRO.2016.03.035</ArticleId><ArticleId IdType="pubmed">27147121</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee J, Lembo A. Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). Aliment Pharmacol Ther. (2021) 54(Suppl 1):S63&#x2013;74. 10.1111/APT.16625</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/APT.16625</ArticleId><ArticleId IdType="pubmed">34927757</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimidi E, Whelan K. Food supplements and diet as treatment options in irritable bowel syndrome. Neurogastroenterol Motil. (2020) 32:e13951. 10.1111/NMO.13951</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/NMO.13951</ArticleId><ArticleId IdType="pubmed">32697018</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. (2017) 66:1517&#x2013;27. 10.1136/GUTJNL-2017-313750</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/GUTJNL-2017-313750</ArticleId><ArticleId IdType="pubmed">28592442</ArticleId></ArticleIdList></Reference><Reference><Citation>Paine P. Review article: current and future treatment approaches for pain in IBS. Aliment Pharmacol Ther. (2021) 54(Suppl 1):S75&#x2013;88. 10.1111/APT.16550</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/APT.16550</ArticleId><ArticleId IdType="pubmed">34927753</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. (2018) 93:1858&#x2013;72. 10.1016/J.MAYOCP.2018.04.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MAYOCP.2018.04.032</ArticleId><ArticleId IdType="pmc">PMC6314474</ArticleId><ArticleId IdType="pubmed">30522596</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Ren X, Li G, Li Y, Zhang L, Wang H, et al. Beneficial effects of rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. (2018) 33:443&#x2013;52. 10.1111/JGH.13841</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JGH.13841</ArticleId><ArticleId IdType="pubmed">28573746</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzhalii E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment. World J Hepatol. (2022) 14:634&#x2013;46. 10.4254/WJH.V14.I3.634</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/WJH.V14.I3.634</ArticleId><ArticleId IdType="pmc">PMC9055191</ArticleId><ArticleId IdType="pubmed">35582294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkach S, Dorofeyev A, Kuzenko I, Boyko N, Falalyeyeva T, Boccuto L, et al. Current status and future therapeutic options for fecal microbiota transplantation. Medicina (Kaunas, Lithuania). (2022) 58:84. 10.3390/MEDICINA58010084</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/MEDICINA58010084</ArticleId><ArticleId IdType="pmc">PMC8780626</ArticleId><ArticleId IdType="pubmed">35056392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzawi T, Hausken T, El-Salhy M. Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation. Scand J Gastroenterol. (2022) 57:792&#x2013;6. 10.1080/00365521.2022.2036809</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2022.2036809</ArticleId><ArticleId IdType="pubmed">35156893</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Haens GR, Jobin C. Fecal microbial transplantation for diseases beyond recurrent clostridium difficile infection. Gastroenterology. (2019) 157:624&#x2013;36. 10.1053/j.gastro.2019.04.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.04.053</ArticleId><ArticleId IdType="pmc">PMC7179251</ArticleId><ArticleId IdType="pubmed">31220424</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal JP, Ding NS, Worley G, Mclaughlin S, Preston S, Faiz OD, et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther. (2017) 45:581&#x2013;92. 10.1111/apt.13905</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13905</ArticleId><ArticleId IdType="pubmed">28008631</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen PH, Hilp&#xfc;sch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. (2018) 3:17&#x2013;24. 10.1016/S2468-1253(17)30338-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30338-2</ArticleId><ArticleId IdType="pubmed">29100842</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvoet T, Joossens M, V&#xe1;zquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. (2021) 160:145&#x2013;57. 10.1053/j.gastro.2020.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.07.013</ArticleId><ArticleId IdType="pubmed">32681922</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r SI, Christensen AH, Lo BZS, Browne PD, G&#xfc;nther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study. Gut. (2018) 67:2107&#x2013;15. 10.1136/gutjnl-2018-316434</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId><ArticleId IdType="pubmed">29980607</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. (2019) 4:675&#x2013;85. 10.1016/S2468-1253(19)30198-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(19)30198-0</ArticleId><ArticleId IdType="pubmed">31326345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G, Ianiro G, Tilg H, Rajili&#xe6;-Stojanovi&#xe6; M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. (2017) 66:569&#x2013;80. 10.1136/GUTJNL-2016-313017</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/GUTJNL-2016-313017</ArticleId><ArticleId IdType="pmc">PMC5529972</ArticleId><ArticleId IdType="pubmed">28087657</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. (1997) 11:395&#x2013;402. 10.1046/J.1365-2036.1997.142318000.X</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/J.1365-2036.1997.142318000.X</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. (2000) 95:999&#x2013;1007. 10.1111/J.1572-0241.2000.01941.X</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/J.1572-0241.2000.01941.X</ArticleId><ArticleId IdType="pubmed">10763950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks C, Drent M, Elfferich M, De Vries J. The fatigue assessment scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. (2018) 24:495&#x2013;503. 10.1097/MCP.0000000000000496</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCP.0000000000000496</ArticleId><ArticleId IdType="pubmed">29889115</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliada A, Syzenko G, Moseiko V, Budovska L, Puchkov K, Perederiy V, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. (2017) 17:120. 10.1186/S12866-017-1027-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12866-017-1027-1</ArticleId><ArticleId IdType="pmc">PMC5440985</ArticleId><ArticleId IdType="pubmed">28532414</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r SI, Boolsen AW, G&#xfc;nther S, Christensen AH, Petersen AM. Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol. (2017) 23:4112&#x2013;20. 10.3748/WJG.V23.I22.4112</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/WJG.V23.I22.4112</ArticleId><ArticleId IdType="pmc">PMC5473130</ArticleId><ArticleId IdType="pubmed">28652664</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol. (2019) 114:1043&#x2013;50. 10.14309/ajg.0000000000000198</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000198</ArticleId><ArticleId IdType="pmc">PMC7257434</ArticleId><ArticleId IdType="pubmed">30908299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. (2019) 50:240&#x2013;8. 10.1111/apt.15330</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15330</ArticleId><ArticleId IdType="pubmed">31136009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. (2022) 12:827395. 10.3389/FCIMB.2022.827395</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCIMB.2022.827395</ArticleId><ArticleId IdType="pmc">PMC8919053</ArticleId><ArticleId IdType="pubmed">35295757</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Zhang X, Zhang N, Yan B, Xu K, Peng L, et al. Fecal microbiota transplantation for patients with irritable bowel syndrome: A meta-analysis of randomized controlled trials. Front Nutr. (2022) 9:890357. 10.3389/FNUT.2022.890357</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNUT.2022.890357</ArticleId><ArticleId IdType="pmc">PMC9202577</ArticleId><ArticleId IdType="pubmed">35719141</ArticleId></ArticleIdList></Reference><Reference><Citation>Myneedu K, Deoker A, Schmulson MJ, Bashashati M. Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. United Eur Gastroenterol J. (2019) 7:1033&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794695</ArticleId><ArticleId IdType="pubmed">31662860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>